Telix Pharmaceuticals Expands with GMP-Grade Radiopharmaceutical Production in Belgium

Reuters
Jun 25
Telix Pharmaceuticals Expands with GMP-Grade Radiopharmaceutical Production in Belgium

Telix Pharmaceuticals Ltd. has announced the successful production and delivery of its first Good Manufacturing Practice $(GMP.UK)$-grade commercial radiopharmaceutical doses from its Telix Manufacturing Solutions facility in Brussels South, Belgium. This milestone marks the expansion of Telix's commercial radiopharmacy capabilities in Europe. The facility, which is one of the largest in Europe, features nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons. This advancement allows Telix to provide GMP-grade products and radiolabelling services, enhancing access to radiopharmaceuticals in Belgium and beyond. The move is expected to significantly impact patient care, particularly in cancer treatment, while supporting future production of important isotopes and radiopharmaceuticals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on June 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10